This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in this post-hoc meta-analysis of three Edition 6 month, phase III, randomised trials. The study aimed to explore the risk of hypoglycaemia with Toujeo® vs insulin glargine 100U/mL in a broad pool of people with T1DM including children over the age of 6.
Find resources and support for your patients who have been prescribed Toujeo®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo®.
You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.
This site is intended for Healthcare Professionals in the Republic of Ireland and contains information on Sanofi Ireland medicine, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a Healthcare Professional in the Republic of Ireland. This site contains promotional information.
.jpg/jcr:content.jpg){kind=logo}
